Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: Role of hemodynamic alterations

Stroke

Volumn 32, Issue 11, 2001, Pages 2641-2647

  Kilic, Ertugrul ^a,b   Bähr, Mathias ^a   Hermann, Dirk M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Hemodynamics; Heparin; Ischemia, focal; Mice; Plasminogen activator, tissue type; Thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; IODOPHENAZONE C 14; TRIPHENYLTETRAZOLIUM; DRUG DERIVATIVE; DYE; IODOPHENAZONE; PHENAZONE; RECOMBINANT PROTEIN; TETRAZOLIUM; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; BRAIN PERFUSION; CONTROLLED STUDY; DRUG EFFECT; HEMODYNAMICS; HISTOPATHOLOGY; HYPERCOAGULABILITY; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; TREATMENT PLANNING; ANIMAL; BRAIN CIRCULATION; BRAIN EDEMA; CEREBRAL ARTERY DISEASE; DOSE RESPONSE; GENETICS; MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMAL; ANTIPYRINE; AUTORADIOGRAPHY; BRAIN EDEMA; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DYES; HEMODYNAMICS; HEPARIN; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TETRAZOLIUM SALTS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0035164372     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/hs1101.097381     Document Type: Article

References (29)

1. Is tissue plasminogen activator a threat to neurons?
2. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice
3. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling
4. Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice
5. Recombinant tissue-plasminogen activator-induced thrombolysis after cerebral thromboembolism in mice
6. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia
7. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats
8. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: Studies in tPA-deficient mice and wild-type mice on a matched genetic background
9. Serine protease inhibitors: Novel therapeutic targets for stroke?
10. A reproducible model of middle cerebral artery occlusion in mice: Hemodynamic, biochemical and magnetic resonance imaging
11. Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice
12. Evolution of brain infarction after transient focal cerebral ischemia in mice
13. Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice
14. Quantitative measurement of local cerebral blood flow in the anesthetized mouse using intraperitoneal [C-14]-iodoantipyrine injection and final arterial heart blood sampling
15. Measurement of local cerebral blood flow with iodo(14C)-antipyrine
16. Excitotoxin induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
17. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus
18. Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro
19. Tissue-type plasminogen activator is involved in the process of neuronal death induced by oxygen-glucose deprivation in culture
20. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures
21. Tissue plasminogen activator for acute ischemic stroke
22. Activity of coagulation and fibrinolysis parameters in animals
23. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro
24. Ischemic thresholds of cerebral protein synthesis and energy state following middle cerebral artery occlusion in rat
25. Pharmacokinetics and systemic fibrinogenolytic effects of human tissue-type plasminogen activator (n-PA) in humans
26. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator
27. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery
28. Risk of immediate heparin after rt-PA therapy in acute ischemic stroke
29. Acute treatment of ischemic stroke